Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | FPR3 | P25089 | 6/20 | 0.40 |
| ▸ | FPR2 | P25090 | 6/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141296 | 0.97 | NPC1 (0.45) | AKT1AKT2NPC1RECQLRAB9A | |
| SCHEMBL2588632 | 0.94 | NPC1 (0.47) | AKT1AKT2NPC1RECQLRAB9A | |
| SCHEMBL18862535 | 0.88 | NPC1 (0.42) | AKT1AKT2NPC1RECQLRAB9A | |
| SCHEMBL14161397 | 0.87 | AKT1 (0.42) | AKT1AKT2RORCFPR2DRD2 | |
| SCHEMBL17448609 | 0.87 | NPC1 (0.46) | AKT1AKT2NPC1RECQLRAB9A | |
| SCHEMBL13047444 | 0.86 | AKT1 (0.41) | AKT1AKT2RORCDRD2PDE2A | |
| SCHEMBL12134686 | 0.86 | AKT1 (0.41) | AKT1AKT2RORCDRD2PDE2A | |
| SCHEMBL10167156 | 0.86 | DRD2 (0.51) | AKT1AKT2DRD2CACNA1B | |
| SCHEMBL17040898 | 0.85 | SSTR4 (0.47) | AKT1AKT2NPC1RAB9A | |
| SCHEMBL10215887 | 0.84 | NPC1 (0.44) | AKT1AKT2NPC1RECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084737-A | Synthesis method of 4- (1- ((tert-butoxycarbonyl) amino) cyclobutyl) benzoic acid | 江苏工程职业技术学院 | 2024-05-28 | — | — | CN | claimed |
| CN-106459036-A | Process of preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3h-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine | 艾科尔公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2024187020-A1 | BIFUNCTIONAL KINASE BINDING COMPOUNDS AND USES THEREOF | PHOTYS THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-118084737-A | Synthesis method of 4- (1- ((tert-butoxycarbonyl) amino) cyclobutyl) benzoic acid | 江苏工程职业技术学院 | 2024-05-28 | — | — | CN | disclosed |
| EP-3362445-B1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-01-25 | — | — | EP | disclosed |
| EP-3362445-B1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-01-25 | — | — | EP | disclosed |
| CN-112457367-B | Interlinking compound as protein degradation agent and preparation method and application thereof | 上海济煜医药科技有限公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-2868660-B1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING AN IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-9834556-B2 | Process of preparing 3-(3-(4-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-B]pyridin-2-YL)pyridin-2-amine | ARQULE, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834556-B2 | Process of preparing 3-(3-(4-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-B]pyridin-2-YL)pyridin-2-amine | ARQULE, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011033265-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2011-03-24 | — | — | WO | disclosed |
| WO-2009148916-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| CN-101600706-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2009-12-09 | — | — | CN | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| WO-2008070016-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161317-A1 | Inhibitors of Akt activity | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885NPC1 1039/4885 |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885NPC1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.